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Abstract
Background: Verona Integron-encoded Metallo-β-lactamase-positive Pseudomonas aeruginosa (VIM-PA) can cause
nosocomial infections and may be responsible for increased mortality. Multidrug resistance in VIM-PA complicates
treatment. We aimed to assess the contribution of VIM-PA to mortality in patients in a large tertiary care hospital in
the Netherlands.
Methods: A focus group of five members created a scheme to define related mortality based on clinical and
diagnostic findings. Contribution to mortality was categorized as “definitely”, “probably”, “possibly”, or “not” related
to infection with VIM-PA, or as “unknown”. Patients were included when infected with or carrier of VIM-PA between
January 2008 and January 2016. Patient-related data and specific data on VIM-PA cultures were retrieved from the
electronic laboratory information system. For patients who died in our hospital, medical records were
independently reviewed and thereafter discussed by three physicians.
Results: A total of 198 patients with any positive culture with VIM-PA were identified, of whom 95 (48.0%) died.
Sixty-seven patients died in our hospital and could be included in the analysis. The death of 15 patients (22.4%)
was judged by all reviewers to be definitely related to infection with VIM-PA. In 17 additional patients (25.4%),
death was probably or possibly related to an infection with VIM-PA. The level of agreement was 65.7% after the first
evaluation, and 98.5% after one session of discussion.
Conclusion: Using our assessment tool, infections with VIM-PA were shown to have an important influence on
mortality in our complex and severely ill patients. The tool may be used for other (resistant) bacteria as well but this
needs further exploration.
Keywords: Pseudomonas aeruginosa, Mortality, Carbapenem, Microbial drug resistance, Infection control, Intensive
care units
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Background
Pseudomonas aeruginosa infections are associated
with substantial morbidity and mortality in hospita-
lised and immunocompromised patients [1–3]. Car-
bapenem resistance in P. aeruginosa isolates is an
emerging problem worldwide, and also in Dutch
hospitals outbreaks have occurred [4–8]. Besides
changes in outer membrane porins and increased
efflux pump activity, carbapenem resistance in P.
aeruginosa can be caused by presence of carbapene-
mase enzymes, of which the metallo-β-lactamases
(MBLs) are the most widespread. In the Netherlands,
the imipenemase (IMP) and Verona Integron-
encoded MBL (VIM) are the most common MBLs in
P. aeruginosa [4]. Studies on various Gram-negative
bacteria suggest that resistance to carbapenem
antibiotics may be responsible for increased mortal-
ity [9, 10]. On the other hand, Carmeli et al. and
Suarez et al. did not demonstrate an association
between baseline resistance to any of four antipseu-
domonal antibiotics tested and adverse outcomes of
patients with a clinical culture positive for P. aerugi-
nosa [11]. Emergence of resistance, however, was
associated with a significantly increased number of
adverse outcomes [11]. The same study group con-
ducted a prospective multicentre study in which car-
bapenem resistance was associated with significantly
increased mortality rates, but the impact on mortal-
ity was higher for less severely ill patients [12]. Still,
data about the attributable mortality of infection
with VIM-positive P. aeruginosa (VIM-PA) are lack-
ing. Furthermore, it is challenging to define and sub-
sequently determine the attributable mortality due to
infection with VIM-PA, since immune status and
host factors play important roles. To assess the
effect of infection with a bacterium on mortality,
large numbers of patients must be included to reach
statistical significance. For VIM-PA in the
Netherlands, these large numbers of inclusion cannot
be reached due to low overall prevalence. Therefore,
different research strategies should be explored to
gain more insight into the effects of VIM-PA on
mortality.
Since 2003, VIM-PA is present in the Erasmus MC
University Medical Center Rotterdam (Erasmus MC),
The Netherlands [4]. Multiple colonisations and infec-
tions occurred and extensive infection prevention
measures were taken [4, 8]. However, the impact on clin-
ical outcome in our patients was not systematically stud-
ied previously. In the current study, we aimed to assess
the contribution of VIM-PA to mortality. For this
purpose, we developed a clinical tool and retrospectively
analysed medical records of all deceased patients with
any positive culture with VIM-PA.
Methods
Setting
The study was performed in the Erasmus MC, a 1200-
bed tertiary-care hospital which has three high-level
adult intensive care (ICU) wards.
Assessment tool
A focus group of five members (two clinical microbiolo-
gists, two residents in clinical microbiology and a clinical
epidemiologist) made a scheme of definitions based on
possible clinical and diagnostic findings, in order to
determine whether death of a patient with any positive
VIM-PA culture could be related to infection with VIM-
PA. This was done before patient data of included
patients were reviewed and was based on clinical experi-
ence of the four medical doctors in the focus group, in
combination with generally accepted definitions of sepsis
described in Additional file 1 [13].
Culture results and sepsis criteria were included by the
focus group because this information was judged to be
crucial in defining related mortality and it could be
obtained fairly objectively. However, cultures are not
always taken for unknown reasons and the used sepsis
criteria from literature are not applicable in every patient
(e.g. in ICU patients who receive medication for support
of vital functions). Furthermore, in complex patients it
may be difficult to interpret clincical findings described
by the patients physician and not all clinically relevant
findings may be documented. Therefore, four categories
were defined which represent a decreasing probablility
that the VIM-PA had contributed to mortality. A fifth
category represented cases in which too little data was
available for a meaningful assessment. In summary,
contribution to mortality was categorized as (i) definitely
related, (ii) probably related, (iii) possibly related, (iv)
not related to infection with VIM-PA, or as (v) unknown
(Table 1). The categories were developed during four
meetings with discussions and were pilot-tested with
data of a few patients before use.
Bacterial isolates
Data on all specimens in which VIM-PA had been found
between 1st January 2008 and 1st January 2016 were
retrieved from the electronic laboratory information
system of the Erasmus MC. After recognition of VIM-
PA in 2008, PCR for detection of blaVIM was introduced
and had been performed on all P. aeruginosa isolates
with intermediate or resistant susceptibility results for
imipenem (MIC ≥8 or disk diffusion of < 17 mm) and
tobramycin (MIC > 4) [4]. This was also done for isolates
with intermediate or resistant susceptibility results for
imipenem in combination with a “highly-resistant micro-
organism (HRMO)” profile. The definitions of HRMO
were issued by the Dutch Working party on Infection
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Prevention (WIP) [14]. A P. aeruginosa isolate was clas-
sified as HRMO when resistance was measured for three
or more of the following antibiotics: aminoglycosides,
fluoroquinolones, ceftazidime, piperacillin and carbapen-
ems. Cultures positive with VIM-PA included screening
cultures as well as clinical cultures.
Prior to 2013, bacterial identification and antibiotic
susceptibility testing was performed using VITEK®2
(Vitek AMS; bioMérieux Vitek Systems Inc., Hazelwood,
MO). Thereafter, the MALDI Biotyper (Matrix Assisted
Laser Desorption Ionization-Time of Flight, Bruker Cor-
poration) was used for bacterial identification to species
level; antibiotic susceptibility testing was continued
using VITEK®2. Antibiotic susceptibility results were
interpreted according to the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) [15].
Clinical data
Patients with a VIM-PA positive culture between 1st
January 2008 and 1st January 2016 from any site who
died in our hospital during this period were included.
Medical records were accessible and reviewed via the
electronic patient system of our hospital. All living pa-
tients had a follow-up of at least 12 months. Patients
were excluded if death occurred outside our hospital,
since we did not have access to patient files from other
hospitals. The following patient characteristics were col-
lected: gender, date of first VIM-PA culture, age at date
of first VIM-PA culture, date of admission, date of death,
nosocomial infection yes/no (positive culture with VIM-
PA > 48 h after admission), ward of acquisition (ward
where the patient was admitted 48 h before identification
of VIM-PA) and Charlson comorbidity index. We used
an updated Charlson comorbidity index to classify co-
morbid conditions. Compared with the original Charlson
index, 12 instead of 17 comorbidities were included and
weights were updated [see Additional file 2] [16].
A clinical review team consisting of two residents in
medical microbiology and one intensivist retrospectively
reviewed all medical records, including diagnostic re-
sults, of the patients who were included in our study.
The members of this clinical review team independently
assessed if mortality was related to sepsis and subse-
quently attempted to identify the source of the infection.
CDC definitions of healthcare-associated infections were
used to help determine whether an infection was present
[5]. They noted their results on a standardized form [see
Additional file 3], with the possibility of adding remarks
and patient specific information. Subsequently, inter-
rater agreement was calculated. In case of disagreement,
the clinical review team discussed the patient. If subse-
quently no agreement could be reached, an independent
infectious disease specialist evaluated the case as a
fourth reviewer. The aim was to reach a minimal inter-
rater agreement of 80%, which corresponds to substan-
tial agreement or almost perfect agreement [17].
Statistical analysis
Patient characteristics and the outcome of the clinical
assessment in categories of related mortality were de-
scribed. The Fleiss’ kappa statistic was used to test inter-
rater agreement.
Table 1 Definitions of categories for the assessment of mortality related to Verona Integron-encoded Metallo-β-lactamase positive
Pseudomonas aeruginosa
Definition Description
Definitely
related
A patient died due to sepsis, severe sepsis or septic shock and had a recent (< 10 days) blood culture with VIM-PA, without other
pathogens in a blood culture.*
Probably
related
A patient died due to sepsis, without a recent positive blood culture (blood cultures were not taken or negative < 10 days of death),
but with a nosocomial infection according to CDC definitions1 AND the strong suspicion of VIM-PA as the pathogen causing sepsis
(cultures from sterile sites e.g.; ascites, abscess, bile, empyema are positive with VIM-PA).
OR
A patient died due to sepsis and had a positive blood culture with VIM-PA longer than 10 days before death but within one month
of death, without another pathogen isolated in blood cultures.
Possibly
related
A patient died due to sepsis and there were cultures with VIM-PA in sterile specimens other than blood cultures within two months
prior to death, with no other cultured possible causative pathogens.
OR
A patient died due to respiratory failure with VIM-PA in respiratory specimens.
Not related The patient did not die due to infection.
AND/OR
The patient was merely colonized with VIM-PA. Colonization was defined as the presence of positive cultures of non-sterile sites with
VIM-PA without signs of infection.
Unknown Insufficient data were available in the medical records.
Abbreviations: VIM-PA: Verona Integron-encoded Metallo-β-lactamase-positive Pseudomonas aeruginosa
*Definitions of sepsis are described in Additional file 1
1 Centers for Disease Control and Prevention. CDC/NHSN surveillance definition of healthcare-associated infection and criteria for specific types of infections in the
acute care setting 2016 [updated January 2016. Available from: https://www.cdc.gov/nhsn/PDFs/pscManual/17pscNosInfDef_current.pdf]
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Results
We developed a clinical tool to assess a possible rela-
tionship between presence of any culture with VIM-PA
and mortality among hospitalised patients (Table 1).
Patient data analyses
A total number of 198 patients with any culture with
VIM-PA between 1st January 2008 and 1st January 2016
were identified of which 95 (48%) had died at the end of
the inclusion period. Of this group, 67 patients deceased
in our hospital (Fig. 1). Patient characteristics are de-
scribed in Table 2. The level of agreement after the first
round of independent review by the clinical review team
was moderate/substantial (65.7% agreement, kappa =
0.62). The level of agreement after one round of discus-
sion was almost perfect (98.5% agreement, kappa = 0.98).
For one patient, agreement could not be reached after
the second round of deliberation, so an infectious dis-
eases specialist evaluated this patient as a fourth re-
viewer. For another patient, all the clinical review team
agreed that too little data was available in the patient
files to draw conclusions. Therefore, this patient was
scored as “unknown”. The patient concerned chose a re-
strictive medical treatment policy and died on the geriat-
ric ward.
The death of 15 patients (22.4%) was judged to be
definitely related to an infection with VIM-PA. These
patients had a recent positive blood culture with
VIM-PA in combination with clinical signs of sepsis
as described in the definitions of related mortality in
Table 1. Furthermore, mortality of 2 (3.0%) patients
was classified as probably related to VIM-PA infection
and 15 (22.4%) patients were categorized in the pos-
sibly related group (Table 2). Figure 2 shows the
number of patients deceased in each year, with a peak
of unrelated deaths in 2011 due to the implementa-
tion of a screening programme on certain wards,
leading to an increase in VIM-PA positive screening
cultures.
In most patients, the bacterium was first detected
at the ICU (73%) and this was the ward on which
93% of the patients of the definitely related group
died. Acquisition of all VIM-PA isolates was nosoco-
mial and the median length of stay (LOS) before the
first VIM-PA culture of the 67 studied patients was
detected was 23 days (range 0–244 days). On admis-
sion, the Charlson scores of the patients in the not
related group were higher than in the definitely, prob-
ably and possibly related group (Charlson score ≥ 4 in
50.1, 26.7, 0 and 20% respectively, Table 2). In
addition, the percentage of patients who died in the
ICU was lower in the not related group compared to
the definitely related group. Most infections were in-
fections of the respiratory and gastro-intestinal tract.
However, some patients had multiple sites of infection
and a single source of the VIM-PA bacteraemia could
not be determined (Table 2).
Time from first VIM-PA positive culture to death
Twenty-four out of 67 deceased patients (35.8%) had a
bacteraemia with VIM-PA. Seven of these 24 patients
(29.2%) had a positive blood culture as the first VIM-PA
culture, of which death of five cases were considered to
be definitely related to infection with VIM-PA. Median
number of days from first VIM-PA positive culture to
death in all included patients was 17 days compared to
6 days in patients with a positive blood culture as the
first VIM-PA positive specimen (Fig. 3).
Fig. 1 Inclusion of patients. Abbreviations: VIM-PA: Verona Integron-encoded Metallo- β- lactamase-positive Pseudomonas aeruginosa. Erasmus
MC: Erasmus MC University Medical Center, Rotterdam, The Netherlands
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Discussion
In this study, we developed a clinical tool consisting
of a set of definitions and a scoring form for the
independent review of patients’ medical charts to
determine the contribution of VIM-PA to mortality.
We applied this on all patients with any VIM-PA
positive culture who had died in our tertiary-care
hospital. Of the 198 patients with a positive VIM-PA
culture in our hospital, the majority (52%) did not die
during the follow-up period. Furthermore, of the
patients who died in our hospital, mortality was not
related to infection with this bacterium in 50.7%.
However, of patients who died in our hospital (n =
67), the death of 15 (22%) patients was definitely re-
lated to an infection with VIM-PA. In an additional
25% of the included patients, death was probably or
possibly related to an infection with VIM-PA. These
results indicate that this nosocomial acquired bacter-
ium had serious clinical impact on our patients.
The ward of acquisition in the majority of cases was
the ICU, and of the definitely related group patients, all
but one had deceased on the ICU. Risk factors for acqui-
sition of VIM-PA may overlap with increased risk of
dying in this patient group. In a study by Voor in ‘t holt
et al., previous use of certain antibiotic regimens (e.g.
use of selective digestive tract decolonisation > 10 days)
and gastroscopy were identified as risk factors for VIM-
PA carriage in the studied population [8].
Nosocomial pneumonia is a leading cause of mortality
in patients with hospital-acquired infections and P. aeru-
ginosa is one of the most important Gram-negative
pathogens of hospital-acquired pneumonia (HAP) and
ventilator-associated pneumonia (VAP) [18, 19]. This
corresponds to our findings that the source of infection
Table 2 Characteristics of included patients (n = 67)
Characteristic Total Definitely
related
Probably
related
Possibly related Not related Unknown
No. of patients (%) 67 (100) 15 (22.4) 2 (3.0) 15 (22.4) 34 (50.7) 1 (1.5)
Male gender (%) 33 (49.3) 10 (66.7) 2 (100) 7 (46.7%) 13 (38.2%) 1 (100)
Mean age at time of first isolation of VIM-PA
(range, SD)
56.6 (18–82,
14.2)
53.0 (20–71,
13.3)
46.1 (40–52,
9.0)
58.3 (34–82,
12.6)
57.5 (18–80,
15.1)
79.1
Mean age at time of death (range, SD) 57.0 (18–82,
14.0)
53.3 (20–71,
13.5)
46.3 (40–53,
8.8)
58.8 (37–82,
11.8)
57.8 (18–81,
15.0)
79.1
Median LOS before first VIM-PA culture, days,
(range)
23 (0–244) 22 (1–244) 85 (80–90) 37 (4–126) 22 (0–202) 0
28-day mortality (%) 36 (53.7) 11 (73.3) 0 (0) 7 (46.7) 17 (50.0) 1 (100)
1-year mortality (%) 61 (91.0) 14 (93.3) 2 (100) 14 (93.3) 30 (88.2) 1 (100)
Location of first VIM-PA; ICU (%) 49 (73.1) 13 (86.7) 0 (0) 13 (86.7) 23 (67.6) 0 (0)
Ward of acquisition; ICU (%) 47 (70.1) 13 (86.7) 0 (0) 12 (80.0) 22 (64.7) 0 (0)
Location of death; ICU (%) 43 (64.2) 14 (93.3) 1 (50.0) 9 (60.0) 19 (55.9) 0 (0)
Nosocomial acquisition 67 (100) 15 (100) 2 (100) 15 (100) 34 (100) 1 (100)
Source of infection
Pneumonia (%) 15 (22.4) 7 (46.7) 1 (50.0) 7 (46.7) 0 (0) 0 (0)
Gastro-intestinal (%) 11 (16.4) 4 (26.7) 1 (50.0) 6 (40.0) 0 (0) 0 (0)
Pneumonia and/or gastro-intestinal (%) 2 (3.0) 1 (6.7) 0 (0) 1 (6.7) 0 (0) 0 (0)
Pneumonia and/or skin and soft tissue (%) 2 (3.0) 2 (13.3) 0 (0) 0 (0) 0 (0) 0 (0)
Gastro-intestinal and/or cardiovascular system
(%)
1 (1.5) 0 (0) 0 (0) 1 (6.7) 0 (0) 0 (0)
Gastro-intestinal and/or skin and soft tissue (%) 1 (1.5) 1 (6.7) 0 (0) 0 (0) 0 (0) 0 (0)
No infection or undetermined (%) 35 (52.2) 0 (0) 0 (0) 0 (0) 34 (100) 1 (100)
Charlson comorbidity scorea
Median Charlson score (range) 3 (0–9)b 2 (0–6)c 0.5 (0–1) 2 (0–5) 4 (1–9)d 4
Abbreviations: No.; number, SD; standard deviation, ICU; intensive care unit, LOS; length of stay, VIM-PA; Verona Integron-encoded Metallo-β-lactamase (VIM)-
positive Pseudomonas aeruginosa
a Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital
discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–82
bFor 2 patients data are missing
cFor 1 patient data are missing
dFor 1 patient data are missing
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with VIM-PA was the respiratory tract in the majority of
the patients (Table 2). Although most of the patients
whose death was related to VIM-PA infection appeared
to be ICU patients and were severely ill, this did not
correspond to the Charlson scores, which is a comorbid-
ity index on admission. The Charlson scores of the
patients in the not related group were higher than in the
definitely, probably and possibly related group (Table 2).
We did not perform statistical analysis on these scores
due to the small numbers but this implies that there
were more severe comorbidities contributing to death,
other than VIM-PA infection in the not related group.
This is in line with admission and re-admission policies
on the ICU where there is a restriction on admitting
patients without any realistic survival chance, which is
carefully assessed by an intensivist. The Charlson comor-
bidity score on admission may not be an accurate esti-
mation of the severity of the illness at the moment of
ICU admission in our study. A possible explanation
could be that these patients suffered from (serious) side
effects of necessary tertiary-care treatments in the
hospital after admission. Once on the ICU, VIM-PA can
Fig. 2 Number of patients deceased (y-axis) in each year (x-axis), n = 67 included patients. Green = definitely related, blue = probably related,
purple = possibly related, white = not related, grey = unknown
Fig. 3 a Time from first detection of Verona Integron-encoded Metallo- β- lactamase-positive Pseudomonas aeruginosa (VIM-PA) in any specimen
to death for all included patients, and (b) time to death in patients with a bacteraemia (i.e. as first culture or as subsequent culture)
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have a clinically significant impact on mortality, also in
patients with few pre-existing comorbidities on hospital
admission.
Studies that evaluated the effect of antibiotic resistance
of Gram-negative bacteria on mortality have produced
contradicting results [9–12, 20–22]. Differences may, in
part, be due to limitations of retrospective study designs,
and the challenges posed to properly control for illness
severity and comorbidities [23]. Although we did not
quantify additional mortality due to VIM-PA in com-
parison to VIM-negative PA, we considered the, in this
study perceived contribution of infection with VIM-PA
to mortality, to be clinically relevant.
P. aeruginosa has the ability to form biofilms [24, 25].
This enables the bacterium to persist in the hospital envir-
onment and together with host-related factors this con-
tributes to the susceptibility of ICU patients for
nosocomial infections with P. aeruginosa. Breathnach et
al. described two outbreaks in the United Kingdom with
VIM-PA. Hospital waste water systems were found to be
potential reservoirs and overall case fatality rate was 34/85
(40%) and 14/18 (78%) in patients who had bacteraemia.
This corresponds to our experience with VIM-PA in our
hospital where rigorous infection prevention measures
were needed to control an outbreak [4, 6, 8].
Our study has several limitations. The clinical tool was
developed to retrospectively assess a possible relation-
ship between death and the presence of a VIM-PA posi-
tive culture. However, due to the complexity of most of
our patients’ medical history, the causality of this rela-
tionship is not proven. Of the patients with a VIM-PA
positive culture in our hospital, the majority did not die
due to infection with VIM-PA within the follow-up
period. Active searching for carriers can have a consider-
able impact on this number. Since we included only de-
ceased patients for further analysis, we have not assessed
the non-lethal complications due to possible VIM-PA in-
fection. Of the initial 95 deceased patients in our study,
28 patients died elsewhere and were not included in our
study. The true number of deaths related to VIM-PA
could therefore be different but not lower than described
in Table 2. The follow-up time was limited to one year
for the last living patient, so possibly VIM-PA could
have contributed to the death of more patients than we
know of. Nevertheless, the median number of days from
the first positive culture with VIM-PA to death was 17
days, so it is likely that our analysis included all relevant
patients. Patients were included from several years and a
peak in unrelated deaths was observed in 2011 due to
the implementation of a screening programme on cer-
tain wards. On the other hand, numbers of VIM-PA re-
lated death per year remained low, making any
interpretation of further analysis on correlation of results
over time not reliable.
Our study results are limited to the patients who died
in our hospital. The retrospective nature of this study
posed limits to the available data we could review. How-
ever, we felt we had sufficient data for all but one patient
to draw a conclusion on related mortality. This was due
to the electronic availability of the patient files. Since
most hospitals in the Netherlands work with electronic
patients files, larger data sets may be analysed in the
future. Currently, electronic hospital information
systems differ between hospitals and data can not always
be extracted in a uniform manner. Therefore, these prac-
tical challenges must be overcome before large scale
analyses of mortality related to infection with (resistant)
bacteria, are possible.
The results of this study may increase awareness about
the presence and possible clinical consequences of a
nosocomially acquired infection of VIM-PA in complex
and vulnerable patients on the ICU. Furthermore, in our
opinion, these results justify the extensive infection con-
trol measures which are needed to prevent spreading of
VIM-PA in a healthcare facillity.
Conclusions
We developed a clinical tool which consisted of a set of
definitions of related mortality and the judgement of
three physicians. With this tool, VIM-PA was shown to
have an important influence on mortality in our tertiary-
care patient population. Our tool may also be used for
the assessment of the influence of other (resistant) bac-
teria on mortality, but this needs further exploration.
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